Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Screen time and skin spots: new study investigates blue Light's effect on melasma

NCT ID NCT03877445

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether blue light from computer and TV screens can make melasma (a common skin condition causing dark patches on the face) worse. Twelve women with melasma had one side of their face exposed to blue light for 30 minutes a day over 5 days, while the other side was not exposed. Researchers measured changes in pigmentation to see if screen-level blue light has any effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Apr 2019

Finished

Jul 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patient, 18 years of age and older, phototype II to V on the Fitzpatrick scale * Patient with a clinically diagnosed diagnosis of melasma. * Patient without a serious medical history and declared fit to participate in the medical visit. * Patient who has signed a written informed consent form before any action related to the study is initiated. * If the patient is able to procreate, she should use reliable contraception (contraceptive pill, contraceptive implant, intrauterine contraceptive device, bilateral tubal ligation / section, condoms), and agree not to change contraceptive status for at least one month before the start of the study and throughout the duration of the study. Exclusion Criteria: * Women who are pregnant or breastfeeding or who have planned a pregnancy during the course of the study. * Patient with another pigment condition on the face. * Patient who used depigmenting cosmetic on the face in the two weeks prior to inclusion. * Patient who used a local corticosteroid on the face or systemic steroids during the month prior to inclusion. * Patient who used local tretinoin or local hydroquinone during the month prior to inclusion. * Patient who took systemic or topical photosensitizing treatments during the month preceding the first day of the study (1 month or 5 half-lives, the longest possible duration), * Patient with a history of photodermatoses. * Patient spending more than 3 hours a day in front of a screen (computer, LED TV, tablet, phone etc ...) for professional or private reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melasma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Melanosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melasma

Contacts and locations

Locations

  • Centre de Pharmacologie Clinique Appliquée à la Dermatologie

    Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.